Centro de Investigación de Medicina Aplicada (CIMA)
Centro / Instituto vinculado a la Universidad de Navarra
Hospital Clinico Universitario de Valencia
Valencia, EspañaPublicaciones en colaboración con investigadores/as de Hospital Clinico Universitario de Valencia (75)
2024
-
Analysis of Tumor Microenvironment Changes after Neoadjuvant Chemotherapy with or without Bevacizumab in Advanced Ovarian Cancer (GEICO-89T/ MINOVA Study)
Clinical Cancer Research, Vol. 30, Núm. 1, pp. 176-186
-
The genomic profiling of high-risk smoldering myeloma patients treated with an intensive strategy unveils potential markers of resistance and progression
Blood cancer journal, Vol. 14, Núm. 1, pp. 74
2023
-
Bariatric Surgery Is Associated with Alcohol-Related Liver Disease and Psychiatric Disorders Associated with AUD
Obesity Surgery, Vol. 33, Núm. 5, pp. 1494-1505
-
Molecular Landscape and Validation of New Genomic Classification in 2668 Adult AML Patients: Real Life Data from the PETHEMA Registry
Cancers, Vol. 15, Núm. 2
-
Transcriptional and genomic characterization of measurable residual disease in acute myeloid leukaemia
British Journal of Haematology
2022
2021
-
Lenalidomide and dexamethasone with or without clarithromycin in patients with multiple myeloma ineligible for autologous transplant: a randomized trial
Blood Cancer Journal, Vol. 11, Núm. 5
-
Measurable residual disease in elderly acute myeloid leukemia: Results from the PETHEMA-FLUGAZA phase 3 clinical trial
Blood Advances, Vol. 5, Núm. 3, pp. 760-770
-
Serum cholesterol predicts transplant-free survival in cirrhotic patients undergoing transjugular intrahepatic portosystemic shunt
Digestive and Liver Disease, Vol. 53, Núm. 12, pp. 1596-1602
-
The mutational landscape of acute myeloid leukaemia predicts responses and outcomes in elderly patients from the pethema-flugaza phase 3 clinical trial
Cancers, Vol. 13, Núm. 10
-
The paediatric cancer clinical research landscape in Spain: a 13-year multicentre experience of the new agents group of the Spanish Society of Paediatric Haematology and Oncology (SEHOP)
Clinical and Translational Oncology, Vol. 23, Núm. 12, pp. 2489-2496
2020
-
Biological and clinical significance of dysplastic hematopoiesis in patients with newly diagnosed multiple myeloma
Blood, Vol. 135, Núm. 26, pp. 2375-2387
-
Networking for advanced molecular diagnosis in acute myeloid leukemia patients is possible: the PETHEMA NGS-AML project
Haematologica, Vol. Online ahead of print
2019
-
A translational approach to assess the metabolomic impact of stabilized gold nanoparticles by NMR spectroscopy
Analyst, Vol. 144, Núm. 4, pp. 1265-1274
-
High serum levels of tissue inhibitor of matrix metalloproteinase-1 during the first week of a malignant middle cerebral artery infarction in non-surviving patients
BMC neurology, Vol. 19, Núm. 1, pp. 167
-
Persistently high circulating tissue inhibitor of matrix metalloproteinase-1 levels in non-survivor brain trauma injury patients
Journal of Critical Care, Vol. 51, pp. 117-121
2018
-
Prognostic value of antigen expression in multiple myeloma: A PETHEMA/GEM study on 1265 patients enrolled in four consecutive clinical trials
Leukemia, Vol. 32, Núm. 4, pp. 971-978
2017
-
Analytical and clinical validation of a novel in-house deep-sequencing method for minimal residual disease monitoring in a phase II trial for multiple myeloma
Leukemia
-
Assessment of gold nanoparticles on human peripheral blood cells by metabolic profiling with 1H-NMR spectroscopy, a novel translational approach on a patient-specific basis
PLoS ONE, Vol. 12, Núm. 8
-
Depth of response in multiple myeloma: A pooled analysis of three PETHEMA/GEM clinical trials
Journal of Clinical Oncology, Vol. 35, Núm. 25, pp. 2900-2910